MACK

8:07 am Merrimack Pharma: Preclinical study results of Merrimack’s MM-141 published in Molecular Cancer Therapeutics; MM-141, a novel bispecific tetravalent antibody, blocks redundant cancer survival pathways

moreView todays social media effects on MACKView the latest stocks trending across Twitter. Click to view dashboardSee who Merrimack is hiring next, click here to view […]

Preclinical Study Results of Merrimack’s MM-141 Published in Molecular Cancer Therapeutics

[GlobeNewswire] – CAMBRIDGE, Mass. — Merrimack Pharmaceuticals, Inc. today announced that the manuscript MM-141, an IGF-1R- and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity … moreView todays social media effects on MACKView the latest stocks trending across Twitter. Click to view dashboardSee who Merrimack is hiring next, click here to view […]

Merrimack Pharmaceuticals Completes Enrollment of One Cohort in Neoadjuvant Phase 2 Study of MM-121 in HER2-Negative Breast Cancer

[at noodls] – CAMBRIDGE, Mass., April 15, 2013 (GLOBE NEWSWIRE) — Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that the last patient has been enrolled in one group of a two-cohort randomized Phase … moreView todays social media effects on MACKView the latest stocks trending across Twitter. Click to view dashboardSee who Merrimack is hiring next, click here to view […]

Merrimack Pharmaceuticals Announces Webcast of Inaugural Research & Development Day

[at noodls] – CAMBRIDGE, Mass., April 5, 2013 (GLOBE NEWSWIRE) — Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that it will hold its inaugural Research & Development Day for analysts and the investor … moreView todays social media effects on MACKView the latest stocks trending across Twitter. Click to view dashboardSee who Merrimack is hiring next, click here to view […]

Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor

[at noodls] – CAMBRIDGE, Mass., April 4, 2013/PRNewswire-USNewswire/ — Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) today announced that one cohort of a Phase 2 non-small cell lung cancer (NSCLC) study did not meet … moreView todays social media effects on MACKView the latest stocks trending across Twitter. Click to view dashboardSee who Merrimack is hiring next, click here to view […]

Merrimack Pharmaceuticals Announces Timing of Fourth Quarter 2012 Investor Conference Call

[at noodls] – CAMBRIDGE, Mass., Feb. 27, 2013 (GLOBE NEWSWIRE) — Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the company will host its Fourth Quarter 2012 Investor Conference Call and webcast … moreView todays social media effects on MACKView the latest stocks trending across Twitter. Click to view dashboardSee who Merrimack is hiring next, click here to view […]

Merrimack to Present at the Cowen and Company 33rd Annual Health Care Conference

[at noodls] – CAMBRIDGE, Mass., Feb. 25, 2013 (GLOBE NEWSWIRE) — Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Robert Mulroy, President & CEO, is scheduled to present at the Cowen and Company 33rd … moreView todays social media effects on MACKView the latest stocks trending across Twitter. Click to view dashboardSee who Merrimack is hiring next, click here to view […]

Merrimack to Participate in Pancreatic Cancer Panel at the 2013 BIO CEO & Investor Conference

[at noodls] – CAMBRIDGE, Mass., Feb. 7, 2013 (GLOBE NEWSWIRE) — Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Peter Laivins, Vice President of Late Stage Clinical Development and Project Leader … moreView todays social media effects on MACKView the latest stocks trending across Twitter. Click to view dashboardSee who Merrimack is hiring next, click here to view […]